Insider Sales at Keros Therapeutics Show Routine Tax‑Withholding, Not Market Worry
Insider sales at Keros Therapeutics are routine sell‑to‑cover moves for tax‑withholding, not a signal of panic—investors should watch clinical milestones and funding rounds for real impact.
3 minutes to read